GHRL and cancer: Major strengths of the present study include the high study participation rate (94%), the exclusion of participants with history of chronic diseases, including type 2 diabetes, cardiovascular disease, and cancer, which may alter the levels of leptin or ghrelin, and the adjustment for potential cofounding variables.